Koyama et al. (2017) found that BRMS1L is one of the mediators downstream of the p53 pathway and inhibits brain cancer invasion and migration. Zhou et al. (2020) revealed that BRMS1L exerted their metastasis-suppressing role by transcriptionally repressing the ITGA7 expression in esophageal squamous cell carcinoma. Recently, Cao et al. (2024) found that the knockdown of BRMS1L expression was correlated with sensitivities to cisplatin-based chemotherapy and conferred anticancer activity in non-small-cell lung cancer by transcriptionally inducing a redox imbalance in the GPX2–ROS pathway. This evidence concerns the gene BRMS1L and brain cancer.